Clinical trial

Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression

Peking University First HospitalNot yet recruitingPhase 4Started Jun 1, 2026164 enrolledChinaNCT07639099

Abstract

Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

ParturientsPrenatal depressive symptomsEsketamineDexmedetomidineIntranasal administrationPostpartum depressionParturientsDepressive SymptomsEsketamineDexmedetomidineIntranasal AdministrationPostpartum Depression

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.